Invest in Amotio and revolutionise revision surgery
Revision joint surgery represents a large and expanding global market with a clear, and currently unmet, need for improved tools and techniques.
Meeting a global, growing need
The joint replacement market is expanding rapidly with the aging population and increased demand for mobility worldwide.
- • Across 13 captured markets approximately 72,000 cemented femoral revision procedures are performed annually.
- • Within the largest single market, the United States, approximately 43,000 cemented and hybrid revision hip arthroplasties take place each year.
And demand is growing due to two main factors:
- • The global population aged 60+ is projected to reach 1.4 billion by 2030, with the World Health Organisation predicting it will rise to 2.1 billion by 2050.
- • Younger patients undergoing joint replacement are likely to require more revisions across their lifetimes.
Together, these factors underpin sustained and long-term growth in the volume of revision surgeries performed annually – supporting a global market worth up to $2bn.
Progress
We have made strong early progress towards commercial readiness, having already raised £1.6m with support from leading UK investors and clinical collaborators.
We’re now seeking £1.5m seed investment to scale our technology.
This investment round marks a significant value inflection point for Amotio as we move towards commercial readiness. Our priorities are:
- • Advancing a low-risk regulatory pathway to market
- • Delivering seamless integration into existing surgical practice
- • Building towards sustainable revenue from 2027
Regulatory and commercial pathway
FDA Class I
Amotio’s innovative precision-guided surgical technology will qualify for an FDA Class I classification, enabling a streamlined route to the US market without the extended clinical requirements associated with higher-risk device categories.
Commercial Readiness
This pathway supports a clear timeline to commercial readiness, with initial US revenue generation expected in 2027.
Speak to the founder
We are currently looking for investors as we progress towards regulatory submission. To learn more or request investor materials, please contact our Founder and CEO Iestyn Foster: iestyn.foster@amotio.health
Contact us